6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Title:
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Author:
Pivot, Xavier Romieu, Gilles Debled, Marc Pierga, Jean-Yves Kerbrat, Pierre Bachelot, Thomas Lortholary, Alain Espié, Marc Fumoleau, Pierre Serin, Daniel Jacquin, Jean-Philippe Jouannaud, Christelle Rios, Maria Abadie-Lacourtoisie, Sophie Venat-Bouvet, Laurence Cany, Laurent Catala, Stéphanie Khayat, David Gambotti, Laetitia Pauporté, Iris Faure-Mercier, Celine Paget-Bailly, Sophie Henriques, Julie Grouin, Jean Marie